We use cookies to improve your website experience. To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy. By closing this message, you are consenting to our use of cookies.

Submit your research today!

Your valuable research in Expert Opinion on Investigational Drugs - Liver cancer

About the special issue

This issue will offer in depth analyses of new molecular targets and drug therapies for hepatocellular carcinoma (HCC); it will provide a birdseye view of key innovations in this rapidly changing field. HCC comprises the majority of liver cancer cases.

A significant percentage of HCCs present with potentially actionable mutations, but translation of this knowledge into the clinic is a work in progress. A handful of systemic therapies are available in the clinic while current clinical trials are examining combination therapies which comprise checkpoint inhibitors and tyrosine kinase inhibitors (TKIs) or anti-VEGF approaches, or immunotherapy combinations.

The outcomes of these trials could transform the therapeutic landscape and impact outcomes for patients.

Be sure to keep up to date with Expert Opinion on Investigational Drugs.

 

Submission Information

3-5 week submission deadline: 1st December 2021
7-9 week submission deadline: 15th December 2021

Learn more about preparing your manuscript by visiting the Instructions for Authors page.

Commissioning Editor: Debbie Tranter

Submit here

By publishing in Expert Opinion on Investigational Drugs you will:

  1. Gain recognition from an international audience and increase your opportunities for future collaboration 
  2. Receive 50 free e-prints & promotional tips on promoting your article courtesy of our Author Services site  
  3. Immediately see the impact of your research made in the community by tracking downloads, citations, and the Altmetric Score of your article on My Authored Works  
  4. Increase the discoverability of your research with MEDLINE listings and more